Cluster composition

Functions

Category	Name	IntersectionWithQuery	PValue	GenesInTerm	GenesInQuery	GenesInTermInQuery	ID
GeneOntologyMolecularFunction	fatty acid elongase activity	ELOVL5 ELOVL1 ELOVL3 ELOVL6	1.42e-09	7	52	4	GO:0009922
GeneOntologyMolecularFunction	3',5'-cGMP-inhibited cyclic-nucleotide phosphodiesterase activity	PDE3A PDE3B	6.65e-06	2	52	2	GO:0004119
GeneOntologyMolecularFunction	phosphoric diester hydrolase activity	PDE3A PDE3B SMPDL3A PLD1	1.18e-04	97	52	4	GO:0008081
GeneOntologyMolecularFunction	acyltransferase activity, transferring groups other than amino-acyl groups	USP22 ELOVL5 ELOVL1 ELOVL3 ELOVL6	3.80e-04	238	52	5	GO:0016747
GeneOntologyMolecularFunction	metal-dependent deubiquitinase activity	EIF3H PRPF8	4.32e-04	12	52	2	GO:0140492
GeneOntologyBiologicalProcess	fatty acid elongation, polyunsaturated fatty acid	ELOVL5 ELOVL1 ELOVL3 ELOVL6	1.25e-09	7	52	4	GO:0034626
GeneOntologyBiologicalProcess	fatty acid elongation, monounsaturated fatty acid	ELOVL5 ELOVL1 ELOVL3 ELOVL6	1.25e-09	7	52	4	GO:0034625
GeneOntologyBiologicalProcess	fatty acid elongation, unsaturated fatty acid	ELOVL5 ELOVL1 ELOVL3 ELOVL6	1.25e-09	7	52	4	GO:0019368
GeneOntologyBiologicalProcess	fatty acid elongation, saturated fatty acid	ELOVL5 ELOVL1 ELOVL3 ELOVL6	2.49e-09	8	52	4	GO:0019367
GeneOntologyBiologicalProcess	very long-chain fatty acid biosynthetic process	ELOVL5 ELOVL1 ELOVL3 ELOVL6	2.52e-08	13	52	4	GO:0042761
GeneOntologyBiologicalProcess	fatty acid elongation	ELOVL5 ELOVL1 ELOVL3 ELOVL6	4.80e-08	15	52	4	GO:0030497
GeneOntologyBiologicalProcess	long-chain fatty-acyl-CoA biosynthetic process	ELOVL5 ELOVL1 ELOVL3 ELOVL6	1.35e-07	19	52	4	GO:0035338
GeneOntologyBiologicalProcess	long-chain fatty-acyl-CoA metabolic process	ELOVL5 ELOVL1 ELOVL3 ELOVL6	6.04e-07	27	52	4	GO:0035336
GeneOntologyBiologicalProcess	fatty-acyl-CoA biosynthetic process	ELOVL5 ELOVL1 ELOVL3 ELOVL6	6.04e-07	27	52	4	GO:0046949
GeneOntologyBiologicalProcess	very long-chain fatty acid metabolic process	ELOVL5 ELOVL1 ELOVL3 ELOVL6	1.77e-06	35	52	4	GO:0000038
GeneOntologyBiologicalProcess	alpha-linolenic acid metabolic process	ELOVL5 ELOVL1 ELOVL3	1.79e-06	10	52	3	GO:0036109
GeneOntologyBiologicalProcess	fatty-acyl-CoA metabolic process	ELOVL5 ELOVL1 ELOVL3 ELOVL6	3.74e-06	42	52	4	GO:0035337
GeneOntologyBiologicalProcess	sphingolipid metabolic process	SMPDL3A ELOVL5 ELOVL1 ELOVL3 ELOVL6 LCT	5.21e-06	176	52	6	GO:0006665
GeneOntologyBiologicalProcess	thioester biosynthetic process	ELOVL5 ELOVL1 ELOVL3 ELOVL6	7.00e-06	49	52	4	GO:0035384
GeneOntologyBiologicalProcess	acyl-CoA biosynthetic process	ELOVL5 ELOVL1 ELOVL3 ELOVL6	7.00e-06	49	52	4	GO:0071616
GeneOntologyBiologicalProcess	fatty acid derivative biosynthetic process	ELOVL5 ELOVL1 ELOVL3 ELOVL6	8.89e-06	52	52	4	GO:1901570
GeneOntologyBiologicalProcess	unsaturated fatty acid biosynthetic process	ELOVL5 ELOVL1 ELOVL3 ELOVL6	1.20e-05	56	52	4	GO:0006636
GeneOntologyBiologicalProcess	ribonucleoside bisphosphate biosynthetic process	ELOVL5 ELOVL1 ELOVL3 ELOVL6	1.69e-05	61	52	4	GO:0034030
GeneOntologyBiologicalProcess	purine nucleoside bisphosphate biosynthetic process	ELOVL5 ELOVL1 ELOVL3 ELOVL6	1.69e-05	61	52	4	GO:0034033
GeneOntologyBiologicalProcess	nucleoside bisphosphate biosynthetic process	ELOVL5 ELOVL1 ELOVL3 ELOVL6	1.69e-05	61	52	4	GO:0033866
GeneOntologyBiologicalProcess	membrane lipid metabolic process	SMPDL3A ELOVL5 ELOVL1 ELOVL3 ELOVL6 LCT	2.33e-05	229	52	6	GO:0006643
GeneOntologyBiologicalProcess	linoleic acid metabolic process	ELOVL5 ELOVL1 ELOVL3	2.58e-05	23	52	3	GO:0043651
GeneOntologyBiologicalProcess	fatty acid derivative metabolic process	ELOVL5 ELOVL1 ELOVL3 ELOVL6	5.43e-05	82	52	4	GO:1901568
GeneOntologyBiologicalProcess	thioester metabolic process	ELOVL5 ELOVL1 ELOVL3 ELOVL6	1.64e-04	109	52	4	GO:0035383
GeneOntologyBiologicalProcess	acyl-CoA metabolic process	ELOVL5 ELOVL1 ELOVL3 ELOVL6	1.64e-04	109	52	4	GO:0006637
GeneOntologyBiologicalProcess	biphenyl catabolic process	UGT2B15 UGT2B17	1.73e-04	8	52	2	GO:0070980
GeneOntologyBiologicalProcess	sphingolipid biosynthetic process	ELOVL5 ELOVL1 ELOVL3 ELOVL6	2.16e-04	117	52	4	GO:0030148
GeneOntologyBiologicalProcess	long-chain fatty acid metabolic process	ELOVL5 ELOVL1 ELOVL3 ELOVL6	2.70e-04	124	52	4	GO:0001676
GeneOntologyBiologicalProcess	biphenyl metabolic process	UGT2B15 UGT2B17	2.77e-04	10	52	2	GO:0018879
GeneOntologyBiologicalProcess	unsaturated fatty acid metabolic process	ELOVL5 ELOVL1 ELOVL3 ELOVL6	3.04e-04	128	52	4	GO:0033559
GeneOntologyBiologicalProcess	xenobiotic glucuronidation	UGT2B15 UGT2B17	4.05e-04	12	52	2	GO:0052697
GeneOntologyBiologicalProcess	purine nucleoside bisphosphate metabolic process	ELOVL5 ELOVL1 ELOVL3 ELOVL6	4.51e-04	142	52	4	GO:0034032
GeneOntologyBiologicalProcess	nucleoside bisphosphate metabolic process	ELOVL5 ELOVL1 ELOVL3 ELOVL6	4.51e-04	142	52	4	GO:0033865
GeneOntologyBiologicalProcess	ribonucleoside bisphosphate metabolic process	ELOVL5 ELOVL1 ELOVL3 ELOVL6	4.51e-04	142	52	4	GO:0033875
GeneOntologyBiologicalProcess	negative regulation of cAMP-mediated signaling	PDE3A PDE3B	5.56e-04	14	52	2	GO:0043951
GeneOntologyBiologicalProcess	membrane lipid biosynthetic process	ELOVL5 ELOVL1 ELOVL3 ELOVL6	6.58e-04	157	52	4	GO:0046467
GeneOntologyBiologicalProcess	amide biosynthetic process	ELOVL5 ELOVL1 ELOVL3 ELOVL6	9.25e-04	172	52	4	GO:0043604
GeneOntologyBiologicalProcess	negative regulation of adenylate cyclase-activating G protein-coupled receptor signaling pathway	PDE3A PDE3B	9.29e-04	18	52	2	GO:0106072
GeneOntologyBiologicalProcess	sulfur compound biosynthetic process	ELOVL5 ELOVL1 ELOVL3 ELOVL6	1.05e-03	178	52	4	GO:0044272
GeneOntologyBiologicalProcess	organophosphate biosynthetic process	MTMR6 TK2 ELOVL5 ELOVL1 ELOVL3 PLD1 ELOVL6	1.11e-03	644	52	7	GO:0090407
GeneOntologyBiologicalProcess	regulation of early endosome to late endosome transport	VPS11 DENND10	1.15e-03	20	52	2	GO:2000641
GeneOntologyBiologicalProcess	venous blood vessel development	CHRD ACVRL1	1.15e-03	20	52	2	GO:0060841
GeneOntologyBiologicalProcess	nucleotide biosynthetic process	TK2 ELOVL5 ELOVL1 ELOVL3 ELOVL6	1.23e-03	319	52	5	GO:0009165
GeneOntologyBiologicalProcess	nucleoside phosphate biosynthetic process	TK2 ELOVL5 ELOVL1 ELOVL3 ELOVL6	1.25e-03	320	52	5	GO:1901293
GeneOntologyBiologicalProcess	cellular glucuronidation	UGT2B15 UGT2B17	1.27e-03	21	52	2	GO:0052695
GeneOntologyBiologicalProcess	fatty acid biosynthetic process	ELOVL5 ELOVL1 ELOVL3 ELOVL6	1.36e-03	191	52	4	GO:0006633
GeneOntologyBiologicalProcess	amide metabolic process	SMPDL3A ELOVL5 ELOVL1 ELOVL3 ELOVL6 LCT	1.74e-03	511	52	6	GO:0043603
GeneOntologyBiologicalProcess	regulation of adenylate cyclase-activating G protein-coupled receptor signaling pathway	PDE3A PDE3B	1.95e-03	26	52	2	GO:0106070
GeneOntologyBiologicalProcess	glucuronate metabolic process	UGT2B15 UGT2B17	1.95e-03	26	52	2	GO:0019585
GeneOntologyBiologicalProcess	uronic acid metabolic process	UGT2B15 UGT2B17	1.95e-03	26	52	2	GO:0006063
Domain	ELO	ELOVL5 ELOVL1 ELOVL3 ELOVL6	1.58e-09	7	50	4	PF01151
Domain	ELO	ELOVL5 ELOVL1 ELOVL3 ELOVL6	1.58e-09	7	50	4	PS01188
Domain	ELO_fam	ELOVL5 ELOVL1 ELOVL3 ELOVL6	1.58e-09	7	50	4	IPR002076
Domain	ELO_CS	ELOVL1 ELOVL3 ELOVL6	3.59e-07	6	50	3	IPR030457
Domain	JAB_MPN	EIF3H PRPF8	4.56e-04	12	50	2	SM00232
Domain	JAB	EIF3H PRPF8	4.56e-04	12	50	2	PF01398
Domain	JAMM/MPN+_dom	EIF3H PRPF8	4.56e-04	12	50	2	IPR000555
Domain	PDEase_I	PDE3A PDE3B	1.43e-03	21	50	2	PF00233
Domain	PDEASE_I	PDE3A PDE3B	1.43e-03	21	50	2	PS00126
Domain	PDEase_CS	PDE3A PDE3B	1.43e-03	21	50	2	IPR023174
Domain	UDPGT	UGT2B15 UGT2B17	1.43e-03	21	50	2	PS00375
Domain	UDPGT	UGT2B15 UGT2B17	1.43e-03	21	50	2	PF00201
Domain	UDP_glucos_trans	UGT2B15 UGT2B17	1.43e-03	21	50	2	IPR002213
Domain	-	PDE3A PDE3B	1.57e-03	22	50	2	1.10.1300.10
Domain	PDEase_catalytic_dom	PDE3A PDE3B	1.71e-03	23	50	2	IPR002073
Domain	HDc	PDE3A PDE3B	1.87e-03	24	50	2	SM00471
Domain	HD/PDEase_dom	PDE3A PDE3B	1.87e-03	24	50	2	IPR003607
Domain	-	MST1R VPS11 WDR11 RIC1	1.20e-02	333	50	4	2.130.10.10
Domain	WD40/YVTN_repeat-like_dom	MST1R VPS11 WDR11 RIC1	1.22e-02	335	50	4	IPR015943
Pathway	WP_ELONGATION_OF_VERY_LONG_CHAIN_FATTY_ACIDS	ELOVL5 ELOVL1 ELOVL3 ELOVL6	3.31e-08	12	42	4	MM17077
Pathway	WP_OMEGA9_FATTY_ACID_SYNTHESIS	ELOVL5 ELOVL1 ELOVL3 ELOVL6	6.67e-08	14	42	4	M39780
Pathway	WP_OMEGA9_FATTY_ACID_SYNTHESIS	ELOVL5 ELOVL1 ELOVL3 ELOVL6	6.67e-08	14	42	4	MM15840
Pathway	REACTOME_SYNTHESIS_OF_VERY_LONG_CHAIN_FATTY_ACYL_COAS	ELOVL5 ELOVL1 ELOVL3 ELOVL6	4.79e-07	22	42	4	MM15451
Pathway	REACTOME_SYNTHESIS_OF_VERY_LONG_CHAIN_FATTY_ACYL_COAS	ELOVL5 ELOVL1 ELOVL3 ELOVL6	6.93e-07	24	42	4	M1016
Pathway	REACTOME_LINOLEIC_ACID_LA_METABOLISM	ELOVL5 ELOVL1 ELOVL3	1.36e-06	8	42	3	MM14822
Pathway	REACTOME_LINOLEIC_ACID_LA_METABOLISM	ELOVL5 ELOVL1 ELOVL3	1.36e-06	8	42	3	M27115
Pathway	REACTOME_FATTY_ACYL_COA_BIOSYNTHESIS	ELOVL5 ELOVL1 ELOVL3 ELOVL6	2.30e-06	32	42	4	MM15446
Pathway	REACTOME_FATTY_ACYL_COA_BIOSYNTHESIS	ELOVL5 ELOVL1 ELOVL3 ELOVL6	4.19e-06	37	42	4	M729
Pathway	REACTOME_ALPHA_LINOLENIC_OMEGA3_AND_LINOLEIC_OMEGA6_ACID_METABOLISM	ELOVL5 ELOVL1 ELOVL3	6.89e-06	13	42	3	MM14821
Pathway	REACTOME_ALPHA_LINOLENIC_OMEGA3_AND_LINOLEIC_OMEGA6_ACID_METABOLISM	ELOVL5 ELOVL1 ELOVL3	6.89e-06	13	42	3	M27114
Pathway	KEGG_DRUG_METABOLISM_OTHER_ENZYMES	TK2 UGT2B15 UGT2B17	4.64e-04	51	42	3	M17726
Pubmed	ELOVL1 production of C24 acyl-CoAs is linked to C24 sphingolipid synthesis.	ELOVL5 ELOVL1 ELOVL3 ELOVL6	1.17e-09	10	55	4	20937905
Pubmed	Impaired epidermal permeability barrier in mice lacking elovl1, the gene responsible for very-long-chain fatty acid production.	ELOVL5 ELOVL1 ELOVL3 ELOVL6	1.83e-09	11	55	4	23689133
Pubmed	Cloning of a human cDNA encoding a novel enzyme involved in the elongation of long-chain polyunsaturated fatty acids.	ELOVL5 ELOVL1 ELOVL3	1.50e-08	4	55	3	10970790
Pubmed	Morphology-based mammalian stem cell tests reveal potential developmental toxicity of donepezil.	ELOVL5 ELOVL1 ELOVL3 ELOVL6	9.56e-08	27	55	4	25269881
Pubmed	Biosynthesis of triacylglycerols.	ELOVL5 ELOVL1 ELOVL3 ELOVL6	1.11e-07	28	55	4	8944226
Pubmed	Phosphodiesterase type 3A (PDE3A), but not type 3B (PDE3B), contributes to the adverse cardiac remodeling induced by pressure overload.	PDE3A PDE3B	2.46e-06	2	55	2	31051182
Pubmed	Novel associations of UDP-glucuronosyltransferase 2B gene variants with prostate cancer risk in a multiethnic study.	UGT2B15 UGT2B17	2.46e-06	2	55	2	24267955
Pubmed	Differential expression of the androgen-conjugating UGT2B15 and UGT2B17 enzymes in prostate tumor cells during cancer progression.	UGT2B15 UGT2B17	2.46e-06	2	55	2	22170718
Pubmed	Phosphodiesterase 3A (PDE3A) deletion suppresses proliferation of cultured murine vascular smooth muscle cells (VSMCs) via inhibition of mitogen-activated protein kinase (MAPK) signaling and alterations in critical cell cycle regulatory proteins.	PDE3A PDE3B	2.46e-06	2	55	2	21632535
Pubmed	Pde3a and Pde3b regulation of murine pulmonary artery smooth muscle cell growth and metabolism.	PDE3A PDE3B	2.46e-06	2	55	2	39435735
Pubmed	Expression of UDP Glucuronosyltransferases 2B15 and 2B17 is associated with methylation status in prostate cancer cells.	UGT2B15 UGT2B17	2.46e-06	2	55	2	32660355
Pubmed	Localization of UDP glucuronosyltransferase gene(s) on mouse chromosome 5.	UGT2B15 UGT2B17	2.46e-06	2	55	2	3105095
Pubmed	UDP-glucuronosyltransferase 2B15 (UGT2B15) and UGT2B17 enzymes are major determinants of the androgen response in prostate cancer LNCaP cells.	UGT2B15 UGT2B17	2.46e-06	2	55	2	17848572
Pubmed	Role of phosphodiesterase type 3A and 3B in regulating platelet and cardiac function using subtype-selective knockout mice.	PDE3A PDE3B	2.46e-06	2	55	2	17482796
Pubmed	Androgen and Estrogen Receptors in Breast Cancer Coregulate Human UDP-Glucuronosyltransferases 2B15 and 2B17.	UGT2B15 UGT2B17	2.46e-06	2	55	2	27496708
Pubmed	The UDP glucuronosyltransferase gene superfamily: suggested nomenclature based on evolutionary divergence.	UGT2B15 UGT2B17	2.46e-06	2	55	2	1909870
Pubmed	Comprehensive Characterization of Mouse UDP-Glucuronosyltransferase (Ugt) Belonging to the Ugt2b Subfamily: Identification of Ugt2b36 as the Predominant Isoform Involved in Morphine Glucuronidation.	UGT2B15 UGT2B17	2.46e-06	2	55	2	28228532
Pubmed	Targeted disruption of PDE3B, but not PDE3A, protects murine heart from ischemia/reperfusion injury.	PDE3A PDE3B	2.46e-06	2	55	2	25877153
Pubmed	A pathophysiological role of PDE3 in allergic airway inflammation.	PDE3A PDE3B	2.46e-06	2	55	2	29367458
Pubmed	Androgen glucuronidation: an unexpected target for androgen deprivation therapy, with prognosis and diagnostic implications.	UGT2B15 UGT2B17	2.46e-06	2	55	2	24121496
Pubmed	Cellular specific expression of the androgen-conjugating enzymes UGT2B15 and UGT2B17 in the human prostate epithelium.	UGT2B15 UGT2B17	2.46e-06	2	55	2	15666817
Pubmed	Mouse UDP glucuronosyltransferase. cDNA and complete amino acid sequence and regulation.	UGT2B15 UGT2B17	2.46e-06	2	55	2	3117546
Pubmed	The uridine diphosphate glucuronosyltransferase 2B15 D85Y and 2B17 deletion polymorphisms predict the glucuronidation pattern of androgens and fat mass in men.	UGT2B15 UGT2B17	2.46e-06	2	55	2	17698910
Pubmed	Copy-number variations (CNVs) of the human sex steroid metabolizing genes UGT2B17 and UGT2B28 and their associations with a UGT2B15 functional polymorphism.	UGT2B15 UGT2B17	7.36e-06	3	55	2	19572376
Pubmed	Regulation of Human UGT2B15 and UGT2B17 by miR-376c in Prostate Cancer Cell Lines.	UGT2B15 UGT2B17	7.36e-06	3	55	2	26163549
Pubmed	Molecular cloning and chromosomal assignment of the human homologue of the rat cGMP-inhibited phosphodiesterase 1 (PDE3A)--a gene involved in fat metabolism located at 11p 15.1.	PDE3A PDE3B	7.36e-06	3	55	2	8921398
Pubmed	Activators of the farnesoid X receptor negatively regulate androgen glucuronidation in human prostate cancer LNCAP cells.	UGT2B15 UGT2B17	7.36e-06	3	55	2	17988216
Pubmed	Production of branched-chain very-long-chain fatty acids by fatty acid elongases and their tissue distribution in mammals.	ELOVL1 ELOVL3	7.36e-06	3	55	2	33069870
Pubmed	Forkhead box protein A1 regulates UDP-glucuronosyltransferase 2B15 gene transcription in LNCaP prostate cancer cells.	UGT2B15 UGT2B17	7.36e-06	3	55	2	20736324
Pubmed	Tissue distribution and relative gene expression of UDP-glucuronosyltransferases (2B7, 2B15, 2B17) in the human fetus.	UGT2B15 UGT2B17	7.36e-06	3	55	2	23223495
Pubmed	Epigenetic regulation of steroid inactivating UDP-glucuronosyltransferases by microRNAs in prostate cancer.	UGT2B15 UGT2B17	7.36e-06	3	55	2	26385605
Pubmed	Impact of phosphodiesterases PDE3 and PDE4 on 5-hydroxytryptamine receptor4-mediated increase of cAMP in human atrial fibrillation.	PDE3A PDE3B	7.36e-06	3	55	2	32949251
Pubmed	Androgen receptor mediates the expression of UDP-glucuronosyltransferase 2 B15 and B17 genes.	UGT2B15 UGT2B17	7.36e-06	3	55	2	18302198
Pubmed	Genetic variations in UGT2B28, UGT2B17, UGT2B15 genes and the risk of prostate cancer: A case-control study.	UGT2B15 UGT2B17	7.36e-06	3	55	2	28882566
Pubmed	The nuclear receptor Shp regulates morphine withdrawal syndrome via modulation of Ugt2b expression in mice.	UGT2B15 UGT2B17	7.36e-06	3	55	2	30689982
Pubmed	Calcitrol (1alpha,25-dihydroxyvitamin D3) inhibits androgen glucuronidation in prostate cancer cells.	UGT2B15 UGT2B17	1.47e-05	4	55	2	18281521
Pubmed	Impacts of the Glucuronidase Genotypes UGT1A4, UGT2B7, UGT2B15 and UGT2B17 on Tamoxifen Metabolism in Breast Cancer Patients.	UGT2B15 UGT2B17	1.47e-05	4	55	2	26176234
Pubmed	The crystal structure of the human Mov34 MPN domain reveals a metal-free dimer.	EIF3H PRPF8	1.47e-05	4	55	2	17559875
Pubmed	Comparative host-coronavirus protein interaction networks reveal pan-viral disease mechanisms.	VPS11 INHBE WDR11 TK2 ELOVL5 PKP2 SCFD1 EIF3H	2.33e-05	754	55	8	33060197
Pubmed	Steroidogenic enzymes and stem cell markers are upregulated during androgen deprivation in prostate cancer.	UGT2B15 UGT2B17	3.67e-05	6	55	2	21365123
Pubmed	Weak activity of UDP-glucuronosyltransferase toward Bisphenol analogs in mouse perinatal development.	UGT2B15 UGT2B17	5.13e-05	7	55	2	26074487
Pubmed	NOTCH1 nuclear interactome reveals key regulators of its transcriptional activity and oncogenic function.	VPS11 WDR11 MED23 PRPF8	5.32e-05	129	55	4	23022380
Pubmed	Simultaneous evaluation of six human glucuronidation activities in liver microsomes using liquid chromatography-tandem mass spectrometry.	UGT2B15 UGT2B17	6.83e-05	8	55	2	22579593
Pubmed	TFIIH is negatively regulated by cdk8-containing mediator complexes.	MED23 CDK7	6.83e-05	8	55	2	10993082
Pubmed	Hetero-oligomer formation of mouse UDP-glucuronosyltransferase (UGT) 2b1 and 1a1 results in the gain of glucuronidation activity towards morphine, an activity which is absent in homo-oligomers of either UGT.	UGT2B15 UGT2B17	6.83e-05	8	55	2	32093886
Pubmed	The configuration of the 17-hydroxy group variably influences the glucuronidation of beta-estradiol and epiestradiol by human UDP-glucuronosyltransferases.	UGT2B15 UGT2B17	6.83e-05	8	55	2	18719240
Pubmed	Associations between polymorphisms in glucuronidation and sulfation enzymes and mammographic breast density in premenopausal women in the United States.	UGT2B15 UGT2B17	6.83e-05	8	55	2	20142249
Pubmed	Expression and misexpression of members of the FGF and TGFbeta families of growth factors in the developing mouse pancreas.	INHBE CHRD ACVRL1	1.60e-04	66	55	3	12666204
Pubmed	Role of UDP-glucuronosyltransferase isoforms in 13-cis retinoic acid metabolism in humans.	UGT2B15 UGT2B17	1.60e-04	12	55	2	20308471
Pubmed	Isolation and characterization of cDNAs corresponding to two human calcium, calmodulin-regulated, 3',5'-cyclic nucleotide phosphodiesterases.	PDE3A PDE3B	1.89e-04	13	55	2	8557689
Pubmed	Inhibition of type 5 phosphodiesterase counteracts β2-adrenergic signalling in beating cardiomyocytes.	PDE3A PDE3B	2.21e-04	14	55	2	25852085
Pubmed	A multi-factor trafficking site on the spliceosome remodeling enzyme BRR2 recruits C9ORF78 to regulate alternative splicing.	MAP1S WDR11 PKP2 MED23 TEX10 PRPF8	2.52e-04	560	55	6	35241646
Pubmed	Quantitative Proteomics Links the LRRC59 Interactome to mRNA Translation on the ER Membrane.	PDE3B PKP2 SCFD1 PRPF8 LRP1B	3.17e-04	375	55	5	32788342
Pubmed	Analysis of early nephron patterning reveals a role for distal RV proliferation in fusion to the ureteric tip via a cap mesenchyme-derived connecting segment.	GREB1 VARS2 ELOVL6	3.49e-04	86	55	3	19501082
Pubmed	Induction of OTUD4 by viral infection promotes antiviral responses through deubiquitinating and stabilizing MAVS.	USP22 EIF3H	3.70e-04	18	55	2	30410068
Pubmed	PRDM16 controls a brown fat/skeletal muscle switch.	OTOP1 ELOVL3	4.13e-04	19	55	2	18719582
Pubmed	Defining the membrane proteome of NK cells.	PDE3B DPY19L1 WDR11 ELOVL5 ELOVL1 PLD1 EIF3H PRPF8	4.74e-04	1168	55	8	19946888
Pubmed	Dorsal root ganglion axon bifurcation tolerates increased cyclic GMP levels: the role of phosphodiesterase 2A and scavenger receptor Npr3.	PDE3A PDE3B	5.06e-04	21	55	2	27740716
Pubmed	Novel loci for adiponectin levels and their influence on type 2 diabetes and metabolic traits: a multi-ethnic meta-analysis of 45,891 individuals.	PDE3A PDE3B	5.06e-04	21	55	2	22479202
Pubmed	Barx2 functions through distinct corepressor classes to regulate hair follicle remodeling.	ELOVL5 ELOVL6	6.63e-04	24	55	2	15728386
Pubmed	Overview of PDEs and their regulation.	PDE3A PDE3B	7.20e-04	25	55	2	17307970
Pubmed	ER-export and ARFRP1/AP-1-dependent delivery of SARS-CoV-2 Envelope to lysosomes controls late stages of viral replication.	PDE3B DPY19L1 WDR11 ELOVL5 ELOVL1 SCFD1 PRPF8	7.28e-04	952	55	7	38569033
Pubmed	The p97/VCP segregase is essential for arsenic-induced degradation of PML and PML-RARA.	MAP1S PKP2 MED23 TEX10	7.94e-04	262	55	4	36880596
Pubmed	HIV-1 Tat protein down-regulates CREB transcription factor expression in PC12 neuronal cells through a phosphatidylinositol 3-kinase/AKT/cyclic nucleoside phosphodiesterase pathway.	PDE3A PDE3B	8.40e-04	27	55	2	11156964
Pubmed	Mass spectrometry-based proteomic analysis of FSCN1-interacting proteins in laryngeal squamous cell carcinoma cells.	PDE3A SCFD1 TEX10	9.22e-04	120	55	3	31298480
Pubmed	Integral and associated lysosomal membrane proteins.	VPS11 WDR11 PLD1	1.06e-03	126	55	3	17897319
Pubmed	CCT chaperonin complex is required for efficient delivery of anthrax toxin into the cytosol of host cells.	VPS11 SCFD1	1.41e-03	35	55	2	23716698
Pubmed	Defects in GPI biosynthesis perturb Cripto signaling during forebrain development in two new mouse models of holoprosencephaly.	CHRD ACVRL1	1.49e-03	36	55	2	23213481
Cytoband	4q13	UGT2B15 UGT2B17	1.46e-04	15	55	2	4q13
GeneFamily	Phosphodiesterases	PDE3A PDE3B	6.25e-04	24	28	2	681
GeneFamily	UDP glucuronosyltransferases	UGT2B15 UGT2B17	1.11e-03	32	28	2	363
Coexpression	GSE30083_SP2_VS_SP4_THYMOCYTE_DN	CYBB PDE3B TK2 SMPDL3A SCFD1 DNAH8	3.49e-06	200	54	6	M5035
ToppCell	Smart-seq2-blood_(Smart-seq2)-myeloid-myeloid_monocytic-classical_monocyte\|blood_(Smart-seq2) / Per Platform+tissue_group, by lineage_subgroup, cell_group, cell_type	CYBB GALNTL5 LAMA3 LRP1B DNAH8	3.07e-06	186	54	5	23b8d51d20b05795a73892d3e20e0f9b6a207820
Drug	imazodan	PDE3A PDE3B ACVRL1	1.50e-06	10	54	3	CID000055917
Drug	glycerol-3-phosphocholine	PDE3A PDE3B SMPDL3A PLD1 ACVRL1 LCT	3.26e-06	172	54	6	CID000000823
Drug	RS-1893	PDE3A PDE3B	5.52e-06	2	54	2	CID000128386
Drug	Inocor (TN)	PDE3A PDE3B	5.52e-06	2	54	2	CID000656683
Drug	SureCN4406168	PDE3A PDE3B	1.65e-05	3	54	2	CID011502028
Drug	SureCN4398032	PDE3A PDE3B	1.65e-05	3	54	2	CID011532088
Drug	SureCN4395097	PDE3A PDE3B	1.65e-05	3	54	2	CID011610011
Drug	SureCN4401117	PDE3A PDE3B	1.65e-05	3	54	2	CID011718172
Drug	SureCN4402206	PDE3A PDE3B	1.65e-05	3	54	2	CID011516917
Drug	WIN 62582	PDE3A PDE3B	1.65e-05	3	54	2	CID005487388
Drug	SureCN4397066	PDE3A PDE3B	1.65e-05	3	54	2	CID011538627
Drug	SureCN4401121	PDE3A PDE3B	1.65e-05	3	54	2	CID011611819
Drug	SureCN4406373	PDE3A PDE3B	1.65e-05	3	54	2	CID011711104
Drug	SureCN4394894	PDE3A PDE3B	1.65e-05	3	54	2	CID011711103
Drug	SureCN5995113	PDE3A PDE3B	1.65e-05	3	54	2	CID011640499
Drug	CHEMBL219123	PDE3A PDE3B	1.65e-05	3	54	2	CID016102624
Drug	SureCN4404748	PDE3A PDE3B	1.65e-05	3	54	2	CID011502895
Drug	germitrine	PDE3A PDE3B	1.65e-05	3	54	2	CID000011217
Drug	SureCN4411840	PDE3A PDE3B	1.65e-05	3	54	2	CID011567407
Drug	SureCN4401113	PDE3A PDE3B	1.65e-05	3	54	2	CID011544858
Drug	SureCN4411688	PDE3A PDE3B	1.65e-05	3	54	2	CID011523192
Drug	SureCN4405038	PDE3A PDE3B	1.65e-05	3	54	2	CID011546172
Drug	SureCN4405912	PDE3A PDE3B	1.65e-05	3	54	2	CID011682920
Drug	SureCN4405883	PDE3A PDE3B	1.65e-05	3	54	2	CID011516351
Drug	SureCN4407211	PDE3A PDE3B	1.65e-05	3	54	2	CID011553351
Drug	pelrinone	PDE3A PDE3B	1.65e-05	3	54	2	CID000055919
Drug	beta-methyllanthionine	VPS11 LCT	1.65e-05	3	54	2	CID000191096
Drug	SureCN4401096	PDE3A PDE3B	1.65e-05	3	54	2	CID011710801
Drug	baciphelacin	VPS11 WDR11 UGT2B15 UGT2B17	2.31e-05	70	54	4	CID000171612
Drug	UK-1745	PDE3A PDE3B	3.30e-05	4	54	2	CID003035852
Drug	R 80122	PDE3A PDE3B	3.30e-05	4	54	2	CID009571043
Drug	isomazole	PDE3A PDE3B	3.30e-05	4	54	2	CID000055689
Drug	nanterinone	PDE3A PDE3B	3.30e-05	4	54	2	CID000071305
Drug	AC1L9KOU	MST1R INHBE CHRD	3.54e-05	27	54	3	CID000447297
Drug	diazo-2	INHBE PDE3A PDE3B	3.96e-05	28	54	3	CID005486722
Drug	adibendan	PDE3A PDE3B	5.50e-05	5	54	2	CID000065867
Drug	enoximone sulfoxide	PDE3A PDE3B	5.50e-05	5	54	2	CID000158474
Drug	saterinone	PDE3A PDE3B	8.23e-05	6	54	2	CID000065874
Drug	EMD 60263	PDE3A PDE3B	8.23e-05	6	54	2	CID000187063
Drug	AWD 122-14	PDE3A PDE3B	8.23e-05	6	54	2	CID000130952
Drug	lorcaserin	UGT2B15 UGT2B17	8.23e-05	6	54	2	ctd:C506658
Drug	RP-217	PDE3A PDE3B	8.23e-05	6	54	2	CID006093445
Drug	Mebendazole [31431-39-7]; Up 200; 13.6uM; MCF7; HT_HG-U133A	MST1R CMKLR2 INHBE GREB1 SYDE1	8.50e-05	189	54	5	2300_UP
Drug	Fatty Acids, Omega-3	ELOVL5 ELOVL3 ELOVL6 SLC30A3	8.65e-05	98	54	4	ctd:D015525
Drug	Tetracycline hydrochloride [64-75-5]; Up 200; 8.4uM; MCF7; HT_HG-U133A	ELOVL5 PKP2 PLD1 SLC30A3 SYDE1	1.01e-04	196	54	5	2243_UP
Drug	Naproxen [22204-53-1]; Up 200; 17.4uM; MCF7; HT_HG-U133A	MTMR6 PKP2 GREB1 SLC30A3 SYDE1	1.06e-04	198	54	5	5457_UP
Drug	0317956-0000 [391210-11-0]; Up 200; 10uM; MCF7; HT_HG-U133A	MST1R INHBE GREB1 PLD1 SYDE1	1.08e-04	199	54	5	3966_UP
Drug	Fatty Acids, Monounsaturated	ELOVL5 ELOVL6	1.15e-04	7	54	2	ctd:D005229
Drug	A844337	PDE3A PDE3B	1.15e-04	7	54	2	CID011704101
Drug	bemoradan	PDE3A PDE3B	1.53e-04	8	54	2	CID005362399
Drug	NSC 45079	PRSS27 LCT	1.53e-04	8	54	2	CID000095966
Drug	taurine-ursodeoxycholate conjugate	ELOVL5 ELOVL3 ELOVL6	1.78e-04	46	54	3	ctd:C030141
Drug	PF-04254644	PDE3A PDE3B	1.97e-04	9	54	2	ctd:C551178
Drug	trequinsin	PDE3A PDE3B	1.97e-04	9	54	2	ctd:C035964
Drug	ICI 89,406	PDE3A PDE3B	1.97e-04	9	54	2	CID000123686
Drug	L-826,141	PDE3A PDE3B	1.97e-04	9	54	2	ctd:C459562
Drug	MKS-492	PDE3A PDE3B	1.97e-04	9	54	2	CID000163931
Drug	LSOs	INHBE CHRD ACVRL1 ELOVL6	2.15e-04	124	54	4	CID000164701
Drug	4-methylumbelliferone	PRSS27 UGT2B15 UGT2B17 LCT	2.73e-04	132	54	4	CID003364573
Drug	MCI-154	PDE3A PDE3B	3.00e-04	11	54	2	CID000123941
Drug	7-methoxycoumarin	PRSS27 UGT2B15 UGT2B17	3.37e-04	57	54	3	CID000010748
Drug	hydron;propane-1,3-diol	INHBE TK2 ACVRL1	3.55e-04	58	54	3	CID005288578
Drug	piroximone	PDE3A PDE3B	3.59e-04	12	54	2	CID000055263
Drug	sulmazole	PDE3A PDE3B	3.59e-04	12	54	2	CID000005353
Drug	DB03443	INHBE CHRD	3.59e-04	12	54	2	CID005287828
Drug	4,4'-hexafluorisopropylidene diphenol	INHBE UGT2B15 UGT2B17 GREB1	3.60e-04	142	54	4	ctd:C583074
Drug	Fatty Acids, Essential	ELOVL5 ELOVL3 ELOVL6	3.73e-04	59	54	3	ctd:D005228
Disease	cholic acid glucuronide measurement	UGT2B15 UGT2B17	8.78e-06	3	51	2	EFO_0800574
Disease	X-25937 measurement	UGT2B15 UGT2B17	1.75e-05	4	51	2	EFO_0800937
Disease	X-24574 measurement	UGT2B15 UGT2B17	6.12e-05	7	51	2	EFO_0800897
Disease	deoxycholic acid glucuronide measurement	UGT2B15 UGT2B17	8.15e-05	8	51	2	EFO_0800575
Disease	4-androsten-3alpha,17alpha-diol monosulfate (3) measurement	UGT2B15 UGT2B17	1.31e-04	10	51	2	EFO_0022090
Disease	DNA repair protein RAD51 homolog 4 measurement	UGT2B15 UGT2B17	1.59e-04	11	51	2	EFO_0801531
Disease	5alpha-androstan-3beta,17beta-diol monosulfate (2) measurement	UGT2B15 UGT2B17	1.91e-04	12	51	2	EFO_0800291
Disease	high density lipoprotein particle size measurement	VPS11 INHBE UGT2B15 UGT2B17	2.15e-04	170	51	4	EFO_0008592
Disease	androstenediol (3alpha, 17alpha) monosulfate (3) measurement	UGT2B15 UGT2B17	2.26e-04	13	51	2	EFO_0800293
Disease	X-19141 measurement	UGT2B15 UGT2B17	2.26e-04	13	51	2	EFO_0800799
Disease	lipid measurement, high density lipoprotein cholesterol measurement	ZNF311 INHBE PDE3A UGT2B15 UGT2B17	2.62e-04	330	51	5	EFO_0004529, EFO_0004612
Disease	5alpha-androstan-3alpha,17alpha-diol monosulfate measurement	UGT2B15 UGT2B17	2.63e-04	14	51	2	EFO_0800283
Disease	pulmonary hypertension (biomarker_via_orthology)	CYBB PDE3A ACVRL1	3.64e-04	80	51	3	DOID:6432 (biomarker_via_orthology)
Disease	5alpha-androstan-3alpha,17beta-diol monosulfate (1) measurement	UGT2B15 UGT2B17	4.40e-04	18	51	2	EFO_0800288
Disease	etiocholanolone glucuronide measurement	UGT2B15 UGT2B17	4.92e-04	19	51	2	EFO_0800362
Disease	androsterone glucuronide measurement	UGT2B15 UGT2B17	5.46e-04	20	51	2	EFO_0800317
Disease	X-24947 measurement	UGT2B15 UGT2B17	6.62e-04	22	51	2	EFO_0800910
Disease	epiandrosterone sulfate measurement	UGT2B15 UGT2B17	8.57e-04	25	51	2	EFO_0021120
Disease	omega-3 polyunsaturated fatty acid measurement	UGT2B15 UGT2B17 SCFD1	1.13e-03	118	51	3	EFO_0010119
Disease	androsterone sulfate measurement	UGT2B15 UGT2B17	1.49e-03	33	51	2	EFO_0021117

Protein segments in the cluster

Peptide	Gene	Start	Entry
HRQDWTILHSYVHLN	DENND10P1	206	Q6NSW5
SLRHVNIDHLHVGWY	EIF3H	106	O15372
TQLWLITHYHEHGSL	ACVRL1	271	P37023
HWLLEALTIDHTHHT	CCDC60	161	Q8IWA6
GHRHWHVVQISSTYL	RIC1	476	Q4ADV7
LIYSWHAITDIQVYH	LRP1B	3251	Q9NZR2
HTWYAETHARHQALG	MAP1S	1021	Q66K74
WHSVAVTIKQHILHL	LAMA3	3241	Q16787
VLIHDHAHWDLVSST	GREB1	766	Q4ZG55
HAHWDLVSSTVHNLY	GREB1	771	Q4ZG55
TWILHHHIASVEKLA	MTMR6	46	Q9Y217
VLHVYHHASMLNIWW	ELOVL5	141	Q9NYP7
WHVTDLHLDPTYHIT	SMPDL3A	41	Q92484
LNTFYIWHNNVLHTH	LINC00312	6	Q9Y6C7
IWHNNVLHTHLVFFL	LINC00312	11	Q9Y6C7
HEAYLSDVIELQWHL	CCDC178	221	Q5BJE1
TLLAEHHITNLGWHT	INHBE	156	P58166
YHNRIHATDVLHAVW	PDE3A	751	Q14432
HATDVLHAVWYLTTQ	PDE3A	756	Q14432
YHNRIHATDVLHAVW	PDE3B	736	Q13370
VVYHTAWIREISQLH	DNAH8	566	Q96JB1
SYTLALAHAVWHHSS	MED23	1206	Q9ULK4
RAVFAAVLHWSHITH	DPY19L1	26	Q2PZI1
AVLHWSHITHLFEND	DPY19L1	31	Q2PZI1
WELRGHHYLHQESLK	RSKR	56	Q96LW2
AHLVLKAHARTWHHY	LCT	571	P09848
LEHHVVHQYWTARPS	TUBGCP5	216	Q96RT8
LEYLEAIHHLHEEWL	TK2	206	O00142
VTHSVHTLLQVYFLW	OTOP1	171	Q7RTM1
KLIFLHWYHHITVLL	ELOVL6	136	Q9H5J4
LIFIHWYHHSTVLVY	ELOVL3	141	Q9HB03
TLQGLEYLHQHWILH	CDK7	121	P50613
ALLFIYLHHNHVSSW	GALNTL5	21	Q7Z4T8
QVTFLHVFHHSVLPW	ELOVL1	136	Q9BW60
HSAIHTIAHLFNVEW	CYBB	111	P04839
HRQDWTILHSYVHLN	DENND10	206	Q8TCE6
HILESQHLWYHRLSI	METTL24	216	Q5JXM2
FKHHIEVLHYLLQSW	SYDE1	586	Q6ZW31
ELSLVTHALHHFWLH	VARS2	801	Q5ST30
PDHVSSTVYLWAHHE	PLD1	451	Q13393
LSWVSDHHHNLLALV	FAM178B	496	Q8IXR5
SIWELTIHHNSYSHH	CMKLR2	266	P46091
WLSLDTHCHLHYEVL	CHRD	556	Q9H2X0
HVHLTWYHTPNVVFI	PRPF8	326	Q6P2Q9
HLVWTHARHLAGYEQ	USP22	246	Q9UPT9
AENHAHHEWYLKIQL	VPS11	506	Q9H270
VYIRVTAHHNWIHRI	PRSS27	261	Q9BQR3
LHYEHQVVQSLHQLW	MYCBPAP	601	Q8TBZ2
LHHTWTYQALVHDVL	SCFD1	271	Q8WVM8
VLLYLTDLDQFLHHW	TEX10	716	Q9NXF1
LHLWALTLTYHVASA	SLC30A3	321	Q99726
FIWNSYLHVHQRIHT	ZNF233	601	A6NK53
HLRVAAHNLTWIQYH	UGT2B15	476	P54855
AHNLTWIQYHSLDVI	UGT2B15	481	P54855
LHFWTVAAHYLHSLS	WDR11	926	Q9BZH6
SHYVWLRDHTQVHTG	VSIG10L2	276	P0DP72
SVLLYSLWAHTELHH	PKP2	841	Q99959
QHLTSAWHLVLSFHD	MST1R	791	Q04912
HLRVAAHNLTWIQYH	UGT2B17	476	O75795
AHNLTWIQYHSLDVI	UGT2B17	481	O75795
FSWHSDLILHEQIHS	ZNF311	256	Q5JNZ3